2018
An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease
Calhoun A, King C, Khoury R, Grossberg GT. An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease. Expert Opinion On Pharmacotherapy 2018, 19: 1711-1717. PMID: 30244611, DOI: 10.1080/14656566.2018.1519022.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAntiparkinson AgentsCholinesterase InhibitorsDonepezilDrug Therapy, CombinationHumansMemantineConceptsAlzheimer's diseaseNMDA receptor antagonist memantineSafety/tolerability dataDisease-modifying treatmentsSevere Alzheimer's diseaseCommon neurodegenerative diseaseMemantine ERTolerability dataTreatment regimenMedication adherenceCombination therapyPoor adherenceCaregiver burdenSocietal burdenDose combinationWarrants further considerationDrug AdministrationCaregiver supportCholinesterase inhibitorsPatientsDonepezilLiterature searchMemantineDiseaseNeurodegenerative diseases
2017
Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer’s disease
Calhoun A, Ko J, Grossberg GT. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer’s disease. Expert Opinion On Emerging Drugs 2017, 22: 101-105. PMID: 28253832, DOI: 10.1080/14728214.2017.1293651.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlzheimer DiseaseAnimalsBenzylaminesDrug DesignHumansIndolesQuinolinesReceptors, SerotoninSerotonin AntagonistsSulfonesConceptsNMDA receptor antagonistAlzheimer's diseaseClinical trialsReceptor antagonistCurrent phase 3 trialsPhase 3 trialCurrent clinical trialsNeuronal cell deathMajor neuropsychiatric disordersSymptom pathophysiologySymptomatic treatmentAD symptomatologyClinical symptomatologyNeuritic plaquesNeurofibrillary tanglesCurrent treatmentPotential treatmentSupplementary treatmentCholinesterase inhibitorsIdalopirdineAge 65Neuropsychiatric disordersAntagonistLiterature searchDisease